What are the advantages of using a noncleavable linker in the Anti-HIgG(Fc)Fab-N-MMAF ADC?

The noncleavable linker provides increased stability of the ADC in the bloodstream, ensuring that the cytotoxic agent MMAF remains attached to the antibody fragment until it is internalized by target cells, thus reducing premature release and off-target toxicity.

Can the Anti-HIgG(Fc)Fab-N-MMAF ADC be used in vivo for animal studies?

While the Anti-HIgG(Fc)Fab-N-MMAF ADC is designed for in vitro pre-screening of human monoclonal antibodies, its application in vivo should be evaluated on a case-by-case basis, considering factors like pharmacokinetics, biodistribution, and specific experimental requirements.

How does glycosylation of the Fc fragment affect the function of the Anti-HIgG(Fc)Fab-N-MMAF ADC?

Glycosylation of the Fc fragment is essential for Fc receptor-mediated activities, ensuring proper binding to receptors and complement proteins. This glycosylation is crucial for mediating physiological effects such as opsonization, ADCC, and degranulation, which can influence the overall efficacy of the ADC.

What are the potential applications of the Anti-HIgG(Fc)Fab-N-MMAF ADC in cancer research?

The Anti-HIgG(Fc)Fab-N-MMAF ADC can be used to evaluate the cytotoxic potential of human monoclonal antibodies targeting cancer cells. By binding to the IgG Fc region, this ADC helps identify promising antibody candidates that effectively deliver the cytotoxic agent MMAF to induce targeted cell death in cancer research models.

How does the Anti-HIgG(Fc)Fab-N-MMAF ADC ensure specificity without a primary antibody?

The Anti-HIgG(Fc)Fab-N-MMAF ADC displays no obvious toxicity without a primary antibody, indicating that the Fab fragment specifically binds to the human IgG Fc region, ensuring that the cytotoxic effects of MMAF are limited to cells expressing the target Fc region.

What role does MMAF play in the function of the Anti-HIgG(Fc)Fab-N-MMAF ADC?

MMAF, the cytotoxic agent in the Anti-HIgG(Fc)Fab-N-MMAF ADC, binds to tubulins, interrupts microtubule dynamics, and induces cell death, making it a potent component for targeted cancer therapy and other research applications involving cell death induction.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-HIgG(Fc)Fab-N-MMAF ADC

anti-HIgG(Fc)Fab-N-MMAF ADC (CAT#: ADC-AA-009)

This ADC product is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-human IgG Fc specific polyclonal antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-009. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Reliable and Economical

This ADC provided reliable results and is a cost-effective alternative for pre-screening human monoclonal antibodies. Highly recommended.

Excellent

Outstanding Performance

The Fab fragment specificity combined with MMAF's cytotoxicity delivered consistent and reproducible outcomes in our assays. Very satisfied!

Excellent

Great Addition to Our Lab

The noncleavable linker ensured stability, and the ADC performed exceptionally well in our pre-screening tests. Excellent quality.

Excellent

Impressive Specificity

The anti-human IgG Fc specificity was spot on. The ADC's design allowed for precise targeting, significantly improving our experimental efficiency.

Excellent

Efficient and Potent

This ADC demonstrated great efficiency in inducing cell death through tubulin binding. It's an indispensable tool in our research arsenal.

Excellent

Exceptional Quality

This ADC provided exceptional quality and consistency in our assays. The glycosylation of the Fc fragment enhanced Fc receptor-mediated activities, greatly benefiting our research.

Q: 1: What are the advantages of using a noncleavable linker in the Anti-HIgG(Fc)Fab-N-MMAF ADC?
A: The noncleavable linker provides increased stability of the ADC in the bloodstream, ensuring that the cytotoxic agent MMAF remains attached to the antibody fragment until it is internalized by target cells, thus reducing premature release and off-target toxicity.
Q: 2: Can the Anti-HIgG(Fc)Fab-N-MMAF ADC be used in vivo for animal studies?
A: While the Anti-HIgG(Fc)Fab-N-MMAF ADC is designed for in vitro pre-screening of human monoclonal antibodies, its application in vivo should be evaluated on a case-by-case basis, considering factors like pharmacokinetics, biodistribution, and specific experimental requirements.
Q: 3: How does glycosylation of the Fc fragment affect the function of the Anti-HIgG(Fc)Fab-N-MMAF ADC?
A: Glycosylation of the Fc fragment is essential for Fc receptor-mediated activities, ensuring proper binding to receptors and complement proteins. This glycosylation is crucial for mediating physiological effects such as opsonization, ADCC, and degranulation, which can influence the overall efficacy of the ADC.
Q: 4: What are the potential applications of the Anti-HIgG(Fc)Fab-N-MMAF ADC in cancer research?
A: The Anti-HIgG(Fc)Fab-N-MMAF ADC can be used to evaluate the cytotoxic potential of human monoclonal antibodies targeting cancer cells. By binding to the IgG Fc region, this ADC helps identify promising antibody candidates that effectively deliver the cytotoxic agent MMAF to induce targeted cell death in cancer research models.
Q: 5: How does the Anti-HIgG(Fc)Fab-N-MMAF ADC ensure specificity without a primary antibody?
A: The Anti-HIgG(Fc)Fab-N-MMAF ADC displays no obvious toxicity without a primary antibody, indicating that the Fab fragment specifically binds to the human IgG Fc region, ensuring that the cytotoxic effects of MMAF are limited to cells expressing the target Fc region.
Q: 6: What role does MMAF play in the function of the Anti-HIgG(Fc)Fab-N-MMAF ADC?
A: MMAF, the cytotoxic agent in the Anti-HIgG(Fc)Fab-N-MMAF ADC, binds to tubulins, interrupts microtubule dynamics, and induces cell death, making it a potent component for targeted cancer therapy and other research applications involving cell death induction.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-050	Protein G-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-055	Protein A-Duocarmycin ADC		Duocarmycins

CAT#	Product Name	Linker	Payload
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-045	anti-Rat IgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-041	anti-Rat IgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-515	Anti-EGFR (ABT-806)-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.